comparemela.com
Home
Live Updates
Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024 : comparemela.com
Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024
– Cabozantinib in combination with atezolizumab reduced the risk of disease progression or death by 35% in patients with metastatic castration-resistant prostate cancer –
– Findings to be...
Related Keywords
Japan
,
United States
,
American
,
Neeraj Agarwal
,
Amy Peterson
,
American Cancer Society
,
European Union
,
University Of Utah
,
Exchange Commission
,
Nasdaq
,
Product Development Medical Affairs
,
Takeda Pharmaceutical Company Limited
,
Clinical Research At Huntsman Cancer Institute
,
Exelixis Inc
,
Facebook
,
Drug Administration
,
American Society Of Clinical Oncology
,
Oral Abstract Session
,
Prostate Cancer
,
American Society
,
Clinical Oncology
,
Cancers Symposium
,
Senior Director
,
Clinical Research
,
Huntsman Cancer Institute
,
Executive Vice President
,
Product Development
,
Medical Affairs
,
Chief Medical Officer
,
Ipsen Pharma
,
Hypertensive Crisis
,
Plantar Erythrodysesthesia
,
Impaired Wound Healing
,
Posterior Leukoencephalopathy Syndrome
,
Fetal Toxicity
,
Prescribing Information
,
Annual Report
,
Quarterly Reports
,
Accessed January
,
Time From Metastasis
,
Overall Survival
,
Castration Resistant Prostate Cancer
,
Results From
,
Metastatic Castration Resistant Prostate Cancer
,
Cancer Prostatic
,
Markets
,
comparemela.com © 2020. All Rights Reserved.